GIP (glucose-dependent insulinotropic polypeptide) has context-dependent pro- and anti-inflammatory effects, and understanding its immunomodulatory role is crucial as GIP/GLP-1 dual agonists like tirzepatide gain widespread use.
Context-dependent inflammation effectsGIP can be both pro- and anti-inflammatory depending on tissue type and metabolic state — a complexity that must be resolved to optimize GIP-based therapies
What the researchers found
GIP's effects on inflammation are context-dependent and influenced by tissue-specific receptor expression and metabolic status. Experimental models show both pro-inflammatory and anti-inflammatory effects depending on the setting. GIP/GLP-1 dual agonists have demonstrated improved glycometabolic and inflammatory outcomes in clinical use, but the individual contributions of each pathway remain unclear.
The GIP receptor (GIPR) is expressed on immune cells and tissues beyond the pancreas, providing a biological basis for immunomodulatory effects. The review highlights GIPR as a promising but understudied target in the emerging field of immunometabolism.
Why it matters
Chronic low-grade inflammation is now recognized as a key driver of type 2 diabetes, obesity, cardiovascular disease, and metabolic syndrome. As millions of patients take tirzepatide and newer dual/triple agonists, understanding GIP's specific contribution to anti-inflammatory effects is essential for optimizing these drugs, identifying which patients benefit most, and developing next-generation therapies that target inflammation more precisely.
How the study worked
Comprehensive narrative review of the scientific literature from GIP's discovery to present, examining preclinical and clinical evidence linking GIP to inflammatory processes. Pharmacological approaches targeting the GIP receptor — including GIP-based multi-target (dual and triple agonist) therapies — are discussed in relation to inflammatory outcomes.
What this study cannot tell us
Clinical data on GIP's anti-inflammatory effects are still limited. Most evidence comes from preclinical models, which may not translate directly to humans. The context-dependent nature of GIP's effects (sometimes pro-inflammatory, sometimes anti-inflammatory) makes it difficult to predict clinical outcomes. The review acknowledges that disentangling GIP from GLP-1 contributions in dual agonist therapies remains an unsolved challenge.
How to read the evidence
This is a narrative review of preclinical and limited clinical literature. While it provides a comprehensive overview of an emerging field, much of the evidence for GIP's immunomodulatory effects comes from experimental models rather than clinical studies.
When this study was published
Published in 2026, this is a very current review reflecting the intense research interest in GIP biology driven by tirzepatide's clinical success and the development of next-generation multi-agonist therapies.
The bigger picture
GIP has long been the neglected incretin — overshadowed by GLP-1 in both research attention and drug development. Tirzepatide's stunning clinical success has forced a reassessment: GIP may contribute far more to metabolic improvement than previously thought. This review positions GIP's anti-inflammatory effects as a potentially major yet underexplored component of dual agonist efficacy, with implications for drug design, patient selection, and our understanding of gut-immune communication.
Questions still open
- Does GIP receptor activation contribute to the cardiovascular benefits of tirzepatide, or is this primarily a GLP-1-mediated effect?
- Could selective GIP receptor agonists be developed as standalone anti-inflammatory therapies for metabolic diseases?
- What tissue-specific factors determine whether GIP promotes or suppresses inflammation in a given context?
Common questions
What is GIP and how is it related to drugs like tirzepatide?
Why can GIP be both pro- and anti-inflammatory?
Read the original research
The role of the incretin GIP in inflammation.
Journal of endocrinological investigation, 49(2), 255-266
Citation
Rossi, Giada; Bucciarelli, Loredana; Cimino, Vincenzo; Fiorina, Paolo. (2026). The role of the incretin GIP in inflammation.. Journal of endocrinological investigation, 49(2), 255-266. https://doi.org/10.1007/s40618-025-02719-w